Buck Institute Launches Healthspan Horizons to Close the Gap Between Lifespan and Health
People are living longer. They are not necessarily living better. The Buck Institute for Research on Aging has announced a new initiative specifically aimed at measuring and extending the years of life…
Healthspan Horizons, launched this week, targets what the institute describes as one of the most urgent unresolved problems in modern medicine: the absence of reliable, standardised ways to measure healthspan. Without valid measurement tools, it is nearly impossible to determine whether an intervention actually extended healthy years or merely postponed death while adding years of disease.
The Buck Institute, based in Novato, California, is one of the world’s leading independent aging research organisations. The new programme brings together scientists, clinicians, and technologists to identify and validate biomarkers capable of reliably tracking healthspan — not just lifespan — across individuals and over time.
Why measuring health is harder than measuring life
Lifespan is binary: you count the years. Healthspan is multidimensional. It spans cognitive function, physical capacity, metabolic health, immune competence, and psychological wellbeing — each requiring separate measurement, longitudinal tracking, and large sample sizes to yield meaningful signals. There is currently no scientific consensus on which combination of biomarkers best represents ‘healthy aging’ as a composite outcome.
This has direct consequences beyond academia. Regulatory agencies including the FDA do not currently recognise aging itself as a disease or treatable indication. That makes it exceedingly difficult to run clinical trials for aging-targeted interventions — there is no accepted primary endpoint against which success can be measured. A validated healthspan biomarker suite could change that calculus, opening a regulatory pathway for therapies that currently have nowhere to go.
Ambition and open questions
Details about specific projects and funding are limited at launch. What the announcement signals is a strategic priority shift: from understanding aging at the molecular level toward accelerating translation into clinically measurable outcomes that matter to patients. Whether Healthspan Horizons delivers the field’s missing measurement tools — or becomes another initiative whose ambitions exceed its outputs — will take years to determine.